Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Feb;36(2):425–428. doi: 10.1128/aac.36.2.425

Treatment of Coxsackievirus A9 myocarditis in mice with WIN 54954.

D M See 1, J G Tilles 1
PMCID: PMC188451  PMID: 1318683

Abstract

The therapeutic efficacy of an experimental antiviral agent, WIN 54954, was evaluated in murine myocardial infection with coxsackievirus A9 (CVA9). Eight-month-old male Swiss Webster mice were inoculated with 1.5 x 10(4) PFU of CVA9, Boston strain 13. WIN 54954, a broad-spectrum antipicornavirus agent, was administered orally in a dose of 0.25, 2.5, 25, 50, 100, or 200 mg/kg of body weight per day on days 1 to 3 after virus inoculation. Control animals received xanthan gum carrier only. Mice were sacrificed on day 4. Myocardial titers of virus were determined and found to be significantly lower in the four highest dose treatment groups (P less than 0.001 for all groups) compared with controls. Heart weights were also significantly lower compared with controls in these four groups (P less than 0.001 for all groups). When mice received 50 mg of WIN 54954 per kg daily beginning at either 48 or 72 h postinoculation, myocardial titers were once again significantly reduced compared with those of controls (P less than 0.001 for both groups). Neurological toxicity was observed in the 100- and 200-mg/kg/day groups but not in the lower-dose groups. Thus, WIN 54954 effectively reduced myocardial CVA9 replication in a murine model.

Full text

PDF
426

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abelmann W. H. Myocarditis and dilated cardiomyopathy. West J Med. 1989 Apr;150(4):458–459. [PMC free article] [PubMed] [Google Scholar]
  2. FEDERICI E. E., LERNER A. M., ABELMANN W. H. Observations on the course of Coxsackie A-9 myocarditis in C3H mice. Proc Soc Exp Biol Med. 1963 Mar;112:672–676. doi: 10.3181/00379727-112-28136. [DOI] [PubMed] [Google Scholar]
  3. Fox M. P., Otto M. J., McKinlay M. A. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother. 1986 Jul;30(1):110–116. doi: 10.1128/aac.30.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Guthrie M., Lodge P. A., Huber S. A. Cardiac injury in myocarditis induced by Coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2 + cytolytic lymphocytes. Cell Immunol. 1984 Oct 15;88(2):558–567. doi: 10.1016/0008-8749(84)90188-6. [DOI] [PubMed] [Google Scholar]
  5. Kaye M. P. The Registry of the International Society for Heart Transplantation: fourth official report--1987. J Heart Transplant. 1987 Mar-Apr;6(2):63–67. [PubMed] [Google Scholar]
  6. LERNER A. M., LEVIN H. S., FINLAND M. Age and susceptibility of mice to Coxsackie A viruses. J Exp Med. 1962 Apr 1;115:745–762. doi: 10.1084/jem.115.4.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lerner A. M., Wilson F. M. Virus myocardiopathy. Prog Med Virol. 1973;15:63–91. [PubMed] [Google Scholar]
  8. Maze S. S., Adolph R. J. Myocarditis: unresolved issues in diagnosis and treatment. Clin Cardiol. 1990 Feb;13(2):69–79. doi: 10.1002/clc.4960130203. [DOI] [PubMed] [Google Scholar]
  9. Otto M. J., Fox M. P., Fancher M. J., Kuhrt M. F., Diana G. D., McKinlay M. A. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1985 Jun;27(6):883–886. doi: 10.1128/aac.27.6.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Robinson J. A., O'Connell J. B., Roeges L. M., Major E. O., Gunnar R. M. Coxsackie B3 myocarditis in athymic mice. Proc Soc Exp Biol Med. 1981 Jan;166(1):80–91. doi: 10.3181/00379727-166-41028. [DOI] [PubMed] [Google Scholar]
  11. See D. M., Tilles J. G. Viral myocarditis. Rev Infect Dis. 1991 Sep-Oct;13(5):951–956. doi: 10.1093/clinids/13.5.951. [DOI] [PubMed] [Google Scholar]
  12. TILLES J. G., ELSON S. H., SHAKA J. A., ABELMANN W. H., LERNER A. M., FINLAND M. EFFECTS OF EXERCISE ON COXSACKIE A9 MYOCARDITIS IN ADULT MICE. Proc Soc Exp Biol Med. 1964 Dec;117:777–782. doi: 10.3181/00379727-117-29696. [DOI] [PubMed] [Google Scholar]
  13. WILSON F. M., HASHIMI A., LERNER A. M. MULTIPLICATION OF BOSTON STRAINS OF COXSACKIEVIRUS A9 IN THE ADULT MOUSE HEART. J Bacteriol. 1965 Aug;90:546–548. doi: 10.1128/jb.90.2.546-548.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Woods M. G., Diana G. D., Rogge M. C., Otto M. J., Dutko F. J., McKinlay M. A. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069–2074. doi: 10.1128/aac.33.12.2069. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES